PMID- 28701892
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220330
IS  - 0513-5710 (Print)
IS  - 1346-8049 (Electronic)
IS  - 0513-5710 (Linking)
VI  - 60
IP  - 2
DP  - 2017 Jun
TI  - A Pilot Study of Post-Operative Adjuvant Vaccine for Advanced Gastric Cancer.
PG  - 101-105
AB  - BACKGROUND: Previously, we had performed a clinical study using human leukocyte 
      antigen (HLA)-A24-binding peptide vaccines containing a combination of novel 
      cancer-testis antigens and anti-angiogenic peptides derived from DEPDC1, URLC10, 
      FOXM1, KIF20A and VEGFR1 for advanced gastric cancer (AGC) patients who were 
      refractory to chemotherapy. We applied the cocktail vaccine to the combination 
      therapy with S-1 for patients with AGC as a post-operative adjuvant therapy and 
      performed this clinical pilot study. METHODS: AGC patients who had curative 
      surgery and were classified as pathologically stage III were enrolled. At each 
      6-week treatment cycle, patients received weekly subcutaneous administration of 
      the cocktail vaccine with 5 continuous injections and one break for the first 4 
      cycles and with bi-weekly injections for the following 4 cycles. S-1 (80 mg/m(2)) 
      was administered orally for 4 weeks with 2-week rest for all 8 cycles. The 
      primary endpoint was the safety of the combination therapy and the secondary was 
      the relative dose intensity for S-1. RESULTS: Fourteen patients were enrolled. 
      Six patients with HLA-A*2402 had received S-1 plus the cocktail vaccine as an 
      adjuvant therapy and the remaining 8 had S-1 monotherapy for eight cycles. Five 
      out of 6 patients subjected to the combination group completed the therapy and 
      one patient discontinued because of Grade 3 injection-site reaction. No adverse 
      events of grade 3 or higher were observed except injection-site reactions shown 
      in 5 out of 6 patients who had vaccine therapy. The mean and median relative dose 
      intensities for S-1 were 75.5% and 88% in the combination group and 67% and 80.5% 
      in S-1. CONCLUSION: The vaccine therapy combined with S-1 was manageable and safe 
      adjuvant therapy for stage III gastric cancer. Furthermore, the optimal relative 
      dose intensity of S-1 was achieved in combination group, although the 
      injection-site reaction should be considered.
FAU - Fujiwara, Yoshiyuki
AU  - Fujiwara Y
AD  - Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular 
      Diseases, Osaka 537-8511, Japan.
AD  - double daggerDivision of Surgical Oncology, Department of Surgery, School of Medicine, 
      Tottori University Faculty of Medicine, Yonago 683-8504, Japan.
FAU - Sugimura, Keijiro
AU  - Sugimura K
AD  - Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular 
      Diseases, Osaka 537-8511, Japan.
FAU - Miyata, Hiroshi
AU  - Miyata H
AD  - Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular 
      Diseases, Osaka 537-8511, Japan.
FAU - Omori, Takeshi
AU  - Omori T
AD  - Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular 
      Diseases, Osaka 537-8511, Japan.
FAU - Nakano, Hiroyuki
AU  - Nakano H
AD  - daggerDepartment of Pharmacy, Osaka Medical Center for Cancer and Cardiovascular 
      Diseases, Osaka 537-8511, Japan.
FAU - Mochizuki, Chie
AU  - Mochizuki C
AD  - daggerDepartment of Pharmacy, Osaka Medical Center for Cancer and Cardiovascular 
      Diseases, Osaka 537-8511, Japan.
FAU - Shimizu, Katsuji
AU  - Shimizu K
AD  - daggerDepartment of Pharmacy, Osaka Medical Center for Cancer and Cardiovascular 
      Diseases, Osaka 537-8511, Japan.
FAU - Saito, Hiroaki
AU  - Saito H
AD  - double daggerDivision of Surgical Oncology, Department of Surgery, School of Medicine, 
      Tottori University Faculty of Medicine, Yonago 683-8504, Japan.
FAU - Ashida, Keigo
AU  - Ashida K
AD  - double daggerDivision of Surgical Oncology, Department of Surgery, School of Medicine, 
      Tottori University Faculty of Medicine, Yonago 683-8504, Japan.
FAU - Honjyo, Soichiro
AU  - Honjyo S
AD  - double daggerDivision of Surgical Oncology, Department of Surgery, School of Medicine, 
      Tottori University Faculty of Medicine, Yonago 683-8504, Japan.
FAU - Nakamura, Yusuke
AU  - Nakamura Y
AD  -  section signThe University of Chicago Knapp Center for Biomedical Discovery, Chicago, IL 
      60637, USA.
FAU - Yano, Masahiko
AU  - Yano M
AD  - Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular 
      Diseases, Osaka 537-8511, Japan.
LA  - eng
PT  - Journal Article
DEP - 20170626
PL  - Japan
TA  - Yonago Acta Med
JT  - Yonago acta medica
JID - 0414002
PMC - PMC5502221
OTO - NOTNLM
OT  - S-1
OT  - adjuvant therapy
OT  - gastric cancer
OT  - immunotherapy
OT  - peptide vaccine
EDAT- 2017/07/14 06:00
MHDA- 2017/07/14 06:01
PMCR- 2017/06/26
CRDT- 2017/07/14 06:00
PHST- 2017/03/17 00:00 [received]
PHST- 2017/04/19 00:00 [accepted]
PHST- 2017/07/14 06:00 [entrez]
PHST- 2017/07/14 06:00 [pubmed]
PHST- 2017/07/14 06:01 [medline]
PHST- 2017/06/26 00:00 [pmc-release]
AID - yam-60-101 [pii]
PST - epublish
SO  - Yonago Acta Med. 2017 Jun 26;60(2):101-105. eCollection 2017 Jun.